Synta Pharmaceuticals (SNTA) Misses Q1 Loss Views by 2c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SNTA Hot Sheet
Price: $0.34 --0%
Financial Fact:
Interest expense, net: 41.78K
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Interest expense, net: 41.78K
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Synta Pharmaceuticals, Inc. (NASDAQ: SNTA) reported Q1 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $660 thousand.
For earnings history and earnings-related data on Synta Pharmaceuticals, Inc. (SNTA) click here.
For earnings history and earnings-related data on Synta Pharmaceuticals, Inc. (SNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- Wells Fargo names top retailing stock amid shifting market dynamics
- Nexxen names Neil Jones interim board chair after AGM
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
